Phase I Study of the Combination of Irinotecan Hydrochloride, Carboplatin, and Dexamethasone for the Treatment of Relapsed or Refractory Malignant Lymphoma

International Journal of Hematology

Volumn 79, Issue 3, 2004, Pages 266-270

  Suzumiya, Junji ^a   Suzushima, Hitoshi ^b   Maeda, Kouichi ^c   Okamura, Seiichi ^d   Utsunomiya, Atae ^e   Shibuya, Tunefumi ^f   Tamura, Kazuo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b NTT West Kyushu Hospital   (Japan)

^c Kokuritsu Miyakonojo Hospital   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^e IMAMURA BUN IN HOSPITAL   (Japan)

^f HAMANOMACHI HOSPITAL   (Japan)

Author keywords

CPT 11; Irinotecan; Lymphoma; Phase I study; Salvage therapy

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HANGE SHASHIN TO; IRINOTECAN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANAPLASTIC CARCINOMA; ANEMIA; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LEUKOPENIA; LIVER TOXICITY; MALE; MANTLE CELL LYMPHOMA; MUSCLE FATIGUE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; SIDE EFFECT; T CELL LYMPHOMA; THROMBOCYTOPENIA; VOMITING;

EID: 2442429643     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.03071     Document Type: Article

References (24)

1. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71:117-122.
2. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994;12:1169-1176.
3. Gutierrez M, Chabner BA, Pearson D, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol. 2000;18:3633-3642.
4. Okamoto M, Maruyama F, Tsuzuki M, et al. Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin [in Japanese]. Rinsho Ketsueki. 1994;35:635-641.
5. Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T. Anti-tumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol. 1988;21:71-74.
6. Ohno R, Okada K, Masaoka T, et al. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol. 1990;8:1907-1912.
7. Tsuda H, Takatsuki K, Ohno R, et al. Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11): CPT-11 Study Group on Hematological Malignancy. Br J Cancer. 1994;70:771-774.
8. Rothenberg ML. CPT-11: an original spectrum of clinical activity. Semin Oncol. 1996;23(suppl 3):21-26.
9. Ota K, Ohno R, Shirakawa S, et al. Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia: the CPT-11 Research Group for Hematological Malignancies [in Japanese]. Gan To Kagaku Ryoho. 1994;21:1047-1055.
10. Akutsu M, Suzuki K, Tsunoda S, Kano Y, Miura Y. Effects of SN-38 in combination with other anticancer agents against Dauji cells [in Japanese]. Gan To Kagaku Ryoho. 1994;21:1607-1611.
11. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumors: Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
12. Tobinai K, Hotta T, Saito H, et al. Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma: CPT-11/Lymphoma Study Group. Jpn J Clin Oncol. 1996;26:455-460.
13. Tobinai K, Kohno A, Shimada Y, et al. Toxicity grading criteria of the Japan Clinical Oncology Group: the Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 1993;23:250-257.
14. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979:48.
15. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51:4187-4191.
16. Takagi T, Saotome T. Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma. Leuk Lymphoma. 2001;4:577-586.
17. Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol. 1992;10:16-20.
18. Takeuchi S, Dobashi K, Fujimoto S, et al. A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer: Research Groups of CPT-11 in Gynecologic Cancers [in Japanese]. Gan To Kagaku Ryoho. 1991;18:1681-1689.
19. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer: CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol. 1993; 11:909-913.
20. Sugiyama K, Omachi K, Fujiwara K, et al. Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience. Cancer. 2002;94:594-600.
21. Naito K, Kobayashi M, Oyama A, et al. Phase II study of carboplatin in malignant lymphoma [in Japanese]. Gan To Kagaku Ryoho. 1988;15:2145-2151.
22. Kano Y, Suzuki K, Akutsu M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer. 1992;50: 604-610.
23. Saotome T, Takagi T, Sakai C, Kumagai K, Tamaru J. Combination chemotherapy with irinotecan and Adriamycin for refractory and relapsed non-Hodgkin's lymphoma. Ann Oncol. 2000;11:115-116.
24. Niitsu N, Iijima K, Chizuka A. Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: a pilot study. Ann Hematol. 2001;80:411-416.